A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07137689
Phase
PHASE1
Status
Completed

Conditions

  • Renal Insufficiency

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.

Key Dates

Start date
Aug 18, 2025
Status verified
Apr 2026
Primary completion
Apr 10, 2026
Completion
Apr 10, 2026

Study Design

Enrollment
32 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3537982 (Normal renal function)
    LY3537982 administered orally.
  • Experimental: LY3537982 (Severe renal impairment)
    LY3537982 administered orally.
  • Experimental: LY3537982 (Moderate renal impairment)
    LY3537982 administered orally.

Primary Outcome Measure

Pharmacokinetics: Maximum Concentration (Cmax) of LY3537982 [ Time Frame: Day 1, Predose up to Day 5 Postdose ]

Locations (4)

FacilityCityStateZIPSite coordinators
Jacksonville Center for Clinical ResearchJacksonvilleFlorida32216-
Panax Clinical ResearchMiami LakesFlorida33014-
Orlando Clinical Research CenterOrlandoFlorida32809-
Genesis Clinical ResearchTampaFlorida33603-

Find similar trials in Jacksonville, FL

By research site
Jacksonville Center for Clinical Research· Jacksonville, FLPanax Clinical Research· Miami Lakes, FLOrlando Clinical Research Center· Orlando, FLGenesis Clinical Research· Tampa, FL

Related Studies